Abstract: A method is disclosed for the treatment of mood disorders, including major depression, by administering an effective mood disorder treating amount of a compound possessing functional antagonist properties for the N-methyl-D-aspartate receptor complex.
Type:
Grant
Filed:
June 18, 1990
Date of Patent:
February 4, 1992
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: Certain bridged tricyclic amine compounds are described as being therapeutically effective in treatments of CNS disorders resulting from neurotoxic damage or neurodegenerative diseases, particularly those CNS disorders resulting from ischemic events. Compounds of particular interest for use as neuroprotective agents are those of the formula ##STR1## wherein each of R.sup.1 and R.sup.2 is independently selected from hydrido, loweralkyl, benzyl and phenyl; wherein each of R.sup.1 through R.sup.7 is independently selected from hydrido, loweralkyl, hydroxy, benzyl, phenyl, loweralkoxy, phenoxy, benzyloxy, halo and haloloweralkyl; wherein R.sup.
Abstract: A biodegradable, low biological toxicity, particulate radiographic contrast medium comprises biodegradable polymeric spheres of average molecular weight average diameter about 10-1,000 nm or about 0.01-1.0 micron carrying in at least radiographic contrasting amount of a radiographically opaque element.A method of obtaining a tomographic image of the body portion of a subject comprises administering to the subject a radiographically-detectable amount of the biodegradable, low-toxicity radiographic medium of claim 1; allowing for the spheres to be taken-up by the body portion; and X-raying an area comprising the body portion.A method of improving the contrast of a tomographic image of a body portion of a subject comprises administering to the subject a radiographically-detectable amount of the biodegradable, low-toxicity radiographic medium of claim 1; allowing for the spheres to be selectively taken-up by the body portion; and X-raying an area comprising the body portion.
Type:
Grant
Filed:
July 10, 1989
Date of Patent:
May 28, 1991
Assignee:
University of Kentucky Research Foundation
Abstract: The use of a compound of formula (I) or a physiologically acceptable salt or hydrate thereof in the treatment, relief or prevention of the effects of cerebral ischaemia ##STR1## Compounds of formula (I) are described in UK Published Patent Application No. 2157691A.The compounds of formula (I) have been found to protect mammals, including man, against neuronal damage resulting from cerebral ischaemia.The preferred compound for use in this indication is (.+-.)-trans-5-fluoro-2,3,3a,9a-tetrahydro-1H-[1,4]-benzodioxino[2,3-c]- pyrrole (formula (I), R=H, R.sup.1 =F, R.sup.2 =H), especially in the form of its hydrochloride salt.
Abstract: Prader-Willi Syndrome is alleviated by administering of a 3-oxo or hydroxy substituted 5-beta-androstan-17-one to an individual having the syndrome.
Type:
Grant
Filed:
July 24, 1989
Date of Patent:
April 9, 1991
Assignees:
Progenics, Inc., Long Island Jewish Medical Center